최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0837480 (2013-03-15) |
등록번호 | US-10143725 (2018-12-04) |
발명자 / 주소 |
|
출원인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 451 |
Methods for treating pain using a protein solution comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, Compositions may also contain white blood cells and platelets.
1. A method for treating osteoarthritis pain in a mammalian subject, comprising locally administering to or near a site of osteoarthritis pain in the subject a composition comprising interleukin-1receptor antagonist (IL-1ra) at a concentration of at least 10,000 pg/ml, soluble tumor necrosis factor-
1. A method for treating osteoarthritis pain in a mammalian subject, comprising locally administering to or near a site of osteoarthritis pain in the subject a composition comprising interleukin-1receptor antagonist (IL-1ra) at a concentration of at least 10,000 pg/ml, soluble tumor necrosis factor-receptor I (sTNF-RI) at a concentration of at least 1,200 pg/ml, soluble interleukin-1 receptor II (sIL-1RII) at a concentration of at least 15,000 pg/ml, and at least two proteins selected from the group consisting of epidermal growth factor (EGF) at a concentration of at least 800 pg/ml, hepatocyte growth factor (HGF) at a concentration of at least 1,000 pg/ml, platelet-derived growth factor BB (PDGF-BB) at a concentration of at least 10,000 pg/ml, soluble tumor necrosis factor-receptor II (sTNF-RII) at a concentration of at least 3,000 pg/ml, platelet-derived growth factor-AB (PDGF-AB) at a concentration of at least 35,00 pg/ml, vascular endothelial growth factor (VEGF) at a concentration of at least 500 pg/ml, and transforming growth factor-β1 (TGF-β1) at a concentration of at least 100,000 pg/ml, wherein treating pain includes reducing pain or eliminating pain at or near the site of administration of the composition. 2. The method according to claim 1, wherein the composition is autologous to the subject. 3. The method according to claim 1, wherein the composition further comprises: white blood cells at a concentration of at least 15,000/μl. 4. A method for treating osteoarthritis pain, comprising topically administering a composition to or near a site of osteoarthritis pain in a subject, the composition comprising: at least 10,000 pg/ml interleukin-1 receptor antagonist (IL-1ra);at least 1,200 pg/ml soluble tumor necrosis factor-receptor I (sTNF-RI);at least 15,000 pg/ml soluble interleukin-1 receptor II (sIL-1RII); andat least 3,000 pg/ml soluble tumor necrosis factor-receptor II (sTNF-RII); wherein treating pain includes reducing pain or eliminating pain at or near the site of administration of the composition. 5. The method according to claim 4, wherein the composition further comprises a supplemental protein selected from the group consisting of insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), and transforming growth factor-β1(TGF-β1), wherein the concentration of the selected supplemental protein in the composition is greater than the concentration of the selected supplemental protein in normal blood. 6. The method according to claim 4, wherein the composition further comprises at white blood cells at a concentration of at least 30,000/μl. 7. A method for treating pain associated with osteoarthritis in a mammalian subject, comprising: obtaining a cytokine-cell suspension from the subject;processing the suspension to produce an protein solution comprising soluble interleukin-1receptor antagonist (IL-1ra) at a concentration of at least 10,000 pg/ml, soluble interleukin-1receptor II (sIL-1RII) at a concentration of at least 15,000 pg/ml, soluble tumor necrosis factor-receptor II (sTNF-RII) at a concentration of at least 3,000 pg/ml, and white blood cells at a concentration of at least 15,000/μl; andadministering the protein solution directly to or near a site of osteoarthritis pain in the subject, wherein treating pain includes reducing pain or eliminating pain at or near the site of administration of the protein solution. 8. The method according to claim 7, wherein the cytokine-cell suspension is obtained from one or more of blood, bone marrow aspirate, adipose tissue, or urine. 9. The method according to claim 7, wherein the cytokine-cell suspension comprises platelet rich plasma, bone marrow aspirate, or a combination thereof. 10. The method according to claim 7, wherein the protein solution has a IL-1ra:interleukin-1β concentration ratio greater than 1,500, a white blood cell concentration of at least about 30,000/μl, or both. 11. The method according to claim 7, wherein processing comprises concentrating the cytokine-cell suspension to produce the protein solution. 12. The method according to claim 7, wherein processing comprises contacting the cytokine cell suspension with a solid extraction material to produce the protein solution and separating the solid extraction material from the protein solution. 13. The method according to claim 12, wherein the solid extraction material comprises corundum, quartz, titanium, dextran, agarose, polyacrylamide, polystyrene, polyethylene, polyvinyl chloride, polypropylene, or a combination thereof. 14. The method according to claim 13, wherein the solid extraction material comprises polyacrylamide. 15. The method according to claim 12, wherein the solid extraction material comprises a bead, fiber, powder, porous material, or a combination thereof. 16. The method according to claim 7, further comprising: obtaining bone marrow aspirate from the subject;concentrating the bone marrow aspirate to produce a concentrated bone marrow aspirate (cBMA); andadministering the cBMA to the subject. 17. The method according to claim 7, wherein processing includes mixing a bone marrow aspirate with the cytokine-cell suspension. 18. The method according to claim 7, further comprising administering to the subject a concomitant therapy. 19. The method according to claim 18, wherein the concomitant therapy comprises administering to the site of osteoarthritis pain a composition comprising hyaluronic acid, collagen, an ant-infective agent, or a combination thereof. 20. The method according to claim 18, wherein the concomitant therapy comprises off loader braces, electrical stimulation, or a combination thereof. 21. The method according to claim 7, wherein administering includes injecting the protein solution into a joint. 22. The method according to claim 7, wherein administering includes injecting the protein solution at or near the site of osteoarthritis pain. 23. The method according to claim 7, wherein administering includes topically delivering the protein solution to a muscle at or near a joint. 24. The method according to claim 7, wherein processing the cytokine-cell suspension provides a dosage for administering to the subject. 25. The method according to claim 7, wherein the osteoarthritis pain is associated with back pain. 26. The method according to claim 7, wherein the cytokine-cell suspension comprises about 55 mls to about 120 mls of the subject's whole blood.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.